hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy.
Elyakim
Eran
E
Rosetta Genomics Ltd., Rehovot, Israel.
Sitbon
Einat
E
Faerman
Alexander
A
Tabak
Sarit
S
Montia
Eve
E
Belanis
Liron
L
Dov
Avital
A
Marcusson
Eric G
EG
Bennett
C Frank
CF
Chajut
Ayelet
A
Cohen
Dalia
D
Yerushalmi
Noga
N